Development of a pharmacist collaborative care program for pulmonary arterial hypertension
- 288 Downloads
Patients with Pulmonary Arterial Hypertension (PAH) require multidisciplinary care. Involving pharmacists in PAH multidisciplinary care teams may enhance patient education and improve medication use. We describe the implementation of a Pharmacist Collaborative Care Program (PCCP) in a PAH referral centre in Grenoble, France. Initiated in 2007, the PCCP program includes a pharmacist intervention whose goals are educational, psychosocial, and technical. During patient interviews, pharmacists make an ‘educational diagnosis’ and provide a patient-specific education session. Patient skills are evaluated at the end of the session. Pharmacists provide feedback to nurses and physicians through a standardized report form and discussion during medical rounds and PAH group meetings. Pharmacists re-evaluate patients’ skills every 3–6 months during multidisciplinary clinical evaluations. The PCCP program for PAH is an established practice in Grenoble and may inform future patient education programs involving pharmacists in France, where legislation has recently been passed to standardize patient education.
KeywordsCollaborative care Hospital Patient education Pharmacist Pulmonary arterial hypertension
We thank I. Debaty, C. Robert, E. Odin, A. Bastin, C. Chat, F. Paramelle, M. Sallée, S. Reydellet, M. Couesmes and N. Gonnet for their participation in the ETHAP training session. We also thank M. Jondot for her valuable assistance and Stephanie Harvard for editing the text.
This work was supported by the French Society of Clinical Pharmacy. The authors are employees of the Grenoble University Hospital, which thus contributed to financing this work.
Conflicts of interests
The content of this article is the sole responsibility of the authors. P. Bedouch and M. Roustit have received financial support for research activities from drug companies including Actelion, Bioprojet, GlaxoSmithKline. P. Bedouch received fees from Actelion for participation in scientific advisory board. C. Pison and his research staff received in the last 5 years from Actelion, GSK, Pfizer, United therapeutics and Lilly fees for speaking, fees for organising education, funds for research and fees for consulting from Actelion. M. Baudrant, S. Quetant, A. Lehmann, C. Chapuis, C. Saint-Raymond and B. Allenet have no commercial association or sources of support that might pose a conflict of interest. All authors have made substantive contributions to the study, and all authors endorse the data and conclusions.
- 7.Fournier C, Mischlich D, d’Ivernois JF, Sandrin-Berthon B, Menard J. Towards promotion, structuring and acknowledgement of patient education activities in France. Patient Educ Couns. 2001;44(1):29–34.Google Scholar
- 8.Ministère de la Santé et des Sports. Décret no 2010-904 du 2 août 2010 relatif aux conditions d’autorisation des programmes d’éducation thérapeutique du patient. Paris; 2010.Google Scholar
- 10.Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, et al. Effect of outpatient pharmacists’ non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010;7:CD000336.Google Scholar
- 12.Lehmann A, Baudrant-Boga M, Bedouch P, Robein-Dobremez MJ, Allenet B, Calop J. Optimization of the dispensation of medicines to out-patients—part two: conception of an information tool for healthcare professionals. J Pharm Clin. 2009;28(2):89–96.Google Scholar
- 13.Allenet B, Bedouch P, Baudrant M, Federspiel I, Berthet S, Detavernier M, et al. From medication history to pharmaceutical anamnesis: a standardised patient interview by clinical pharmacists in hospital. J Pharm Belg. 2010;(2):39–46.Google Scholar